Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
RIVASTIGMINE
Accord Healthcare Limited
N06DA03
RIVASTIGMINE
6 Milligram
Capsules Hard
Product subject to prescription which may not be renewed (A)
Anticholinesterases
Authorised
2018-04-20
* Please note that ONLY Artwork Studio is permitted to make changes to the above artwork. No changes are permitted by any 3rd party other than added notes and mark ups for required changes. approved for print/date PROOF ROUND UK-Eire-Artwork-Support@Actavis.com Technical Approval NON PRINTING COLOURS COLOURS DATE SENT: DATE RECEIVED: Item no: ORIGINATOR: ORIGINATION DATE: REVISION DATE: REVISED BY: DIMENSIONS: MIN BODY TEXT SIZE: SUPPLIER: 1. 2. 3. 4. 5. 6. 1. 2. 3. RIVASTIGMINE 1.5MG, 3MG, 4.5MG AND 6MG HARD CAPSULES UK_IRE Black Code Area BBBA1195 C.Grant 23/08/17 20/09/17 S.Anson 170 x 440 9pts Specifar S.A. 24/08/17 11/09/17 03 _Continued top of next column_ BBBA1195 PACKAGE LEAFLET: INFORMATION FOR THE USER _Continued over page_ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • The full name of this medicine is Rivastigmine 1.5mg, 3mg, 4.5mg and 6mg Hard Capsules but within this leaflet it will be referred to as Rivastigmine Capsules. WHAT IS IN THIS LEAFLET: 1 WHAT RIVASTIGMINE CAPSULES ARE AND WHAT THEY ARE USED FOR 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE RIVASTIGMINE CAPSULES 3 HOW TO TAKE RIVASTIGMINE CAPSULES 4 POSSIBLE SIDE EFFECTS 5 HOW TO STORE RIVASTIGMINE CAPSULES 6 CONTENTS OF THE PACK AND OTHER INFORMATION 1 WHAT RIVASTIGMINE CAPSULES ARE AND WHAT THEY ARE USED FOR The active substance of Rivastigmine Capsules is rivastigmine. Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer’s dementia or dementia due to Parkinson’s disease, Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rivastigmine 6 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains rivastigmine hydrogen tartrate corresponding to 6 mg rivastigmine. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard capsule (Capsule). Off-white to slightly yellow powder in a hard capsule with red cap and orange body, with red imprint “RIV 6mg” on body. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia or dementia associated with Parkinson’s disease. Diagnosis should be made according to current guidelines. Therapy with rivastigmine should only be started if a caregiver is available who will regularly monitor intake of the medicinal product by the patient. Posology Rivastigmine should be administered twice a day, with morning and evening meals. The capsules should be swallowed whole. _Initial dose_ 1.5 mg twice a day. _Dose titration_ The starting dose is 1.5 mg twice a day. If this dose is well tolerated after a minimum of two weeks of treatment, the dose may be increased to 3 mg twice a day. Subsequent increases to 4.5 mg and then 6 mg twice a day should also be based on good tolerability of the current dose and may be considered after a minimum of two weeks of treatment at that dose level. If adverse reactions (e.g. nausea, vomiting, abdominal pain or loss of appetite), weight decrease or worsening of extrapyramidal symptoms (e.g. tremor) in patients with dementia associated with Parkinson’s disease are observed during treatment, these may respond to omitting one or more doses. If adverse reactions persist, the daily dose should be temporarily reduced to the pre Read the complete document